MX2012004703A - Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. - Google Patents
Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.Info
- Publication number
- MX2012004703A MX2012004703A MX2012004703A MX2012004703A MX2012004703A MX 2012004703 A MX2012004703 A MX 2012004703A MX 2012004703 A MX2012004703 A MX 2012004703A MX 2012004703 A MX2012004703 A MX 2012004703A MX 2012004703 A MX2012004703 A MX 2012004703A
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- complexed
- column
- toxin
- complex
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 212
- 238000000034 method Methods 0.000 title claims abstract description 143
- 231100001103 botulinum neurotoxin Toxicity 0.000 title abstract description 8
- 229940053031 botulinum toxin Drugs 0.000 claims description 186
- 230000008569 process Effects 0.000 claims description 62
- 239000000047 product Substances 0.000 claims description 59
- 238000000855 fermentation Methods 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 47
- 230000004151 fermentation Effects 0.000 claims description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 43
- 108700012359 toxins Proteins 0.000 claims description 42
- 239000003053 toxin Substances 0.000 claims description 41
- 231100000765 toxin Toxicity 0.000 claims description 41
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 34
- 239000000872 buffer Substances 0.000 claims description 34
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 26
- 239000003480 eluent Substances 0.000 claims description 25
- 101710163270 Nuclease Proteins 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 22
- 239000002244 precipitate Substances 0.000 claims description 20
- 238000009295 crossflow filtration Methods 0.000 claims description 18
- 238000011068 loading method Methods 0.000 claims description 18
- 230000003993 interaction Effects 0.000 claims description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 229920002684 Sepharose Polymers 0.000 claims description 13
- 125000002091 cationic group Chemical group 0.000 claims description 13
- 238000005349 anion exchange Methods 0.000 claims description 12
- 238000005341 cation exchange Methods 0.000 claims description 12
- 230000029087 digestion Effects 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 8
- 125000000129 anionic group Chemical group 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- 230000001174 ascending effect Effects 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 238000003916 acid precipitation Methods 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000007987 MES buffer Substances 0.000 claims 1
- IRHWMYKYLWNHTL-UHFFFAOYSA-M sodium 2-(N-morpholino)ethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCN1CCOCC1 IRHWMYKYLWNHTL-UHFFFAOYSA-M 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 33
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 23
- 231100000252 nontoxic Toxicity 0.000 description 22
- 230000003000 nontoxic effect Effects 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 238000001914 filtration Methods 0.000 description 19
- 238000011210 chromatographic step Methods 0.000 description 17
- 239000012535 impurity Substances 0.000 description 15
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 14
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 14
- 235000011130 ammonium sulphate Nutrition 0.000 description 14
- 238000005119 centrifugation Methods 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 238000005352 clarification Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 238000011097 chromatography purification Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241001112695 Clostridiales Species 0.000 description 8
- 241000193155 Clostridium botulinum Species 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 101710154606 Hemagglutinin Proteins 0.000 description 7
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 7
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 7
- 101710176177 Protein A56 Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000002581 neurotoxin Substances 0.000 description 6
- 231100000618 neurotoxin Toxicity 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000021120 animal protein Nutrition 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000003508 Botulism Diseases 0.000 description 4
- 239000012619 Butyl Sepharose® Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 101710138657 Neurotoxin Proteins 0.000 description 4
- 239000012614 Q-Sepharose Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 206010044074 Torticollis Diseases 0.000 description 3
- 229940089093 botox Drugs 0.000 description 3
- 201000002866 cervical dystonia Diseases 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 230000002887 neurotoxic effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011118 depth filtration Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000006047 digesta Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241001637621 Lupinus campestris Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 108010069022 botulinum toxin type D Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012434 mixed-mode chromatography Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000009340 pathogen transmission Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- -1 salt ions Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940018272 xeomin Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25381009P | 2009-10-21 | 2009-10-21 | |
| PCT/US2010/053389 WO2011050072A1 (en) | 2009-10-21 | 2010-10-20 | Methods and systems for purifying non-complexed botulinum neurotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012004703A true MX2012004703A (es) | 2012-06-08 |
Family
ID=43879799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004703A MX2012004703A (es) | 2009-10-21 | 2010-10-20 | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
| MX2015011592A MX365496B (es) | 2009-10-21 | 2010-10-20 | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
| MX2019006519A MX2019006519A (es) | 2009-10-21 | 2012-04-20 | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011592A MX365496B (es) | 2009-10-21 | 2010-10-20 | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
| MX2019006519A MX2019006519A (es) | 2009-10-21 | 2012-04-20 | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
Country Status (24)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2379104T (lt) | 2008-12-31 | 2018-04-10 | Revance Therapeutics, Inc. | Injekcinės botulino toksino vaisto formos |
| CN102869373B (zh) * | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| US20120196349A1 (en) * | 2009-10-21 | 2012-08-02 | Revance Therapeutics, Inc. | Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin |
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| KR102272580B1 (ko) | 2013-07-30 | 2021-07-05 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도 |
| KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| CA3124535A1 (en) | 2018-12-21 | 2020-06-25 | The Research Foundation For Microbial Diseases Of Osaka University | Botulinum toxin producing method |
| KR102485146B1 (ko) | 2019-04-15 | 2023-01-06 | (주)제테마 | 보툴리눔 독소의 제조방법 |
| KR102447441B1 (ko) * | 2019-04-15 | 2022-09-27 | (주)제테마 | 보툴리눔 독소의 정제방법 |
| US10851363B1 (en) * | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
| KR20230146049A (ko) * | 2021-02-26 | 2023-10-18 | 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 | 폴리펩티드를 제조하기 위한 세포 용해 버퍼 분리 장비, 시스템 및 이의 용도 |
| CN114958887B (zh) * | 2021-02-26 | 2024-10-25 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| KR102724650B1 (ko) * | 2021-07-05 | 2024-11-01 | 주식회사 파마리서치바이오 | 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법 |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| KR102512757B1 (ko) * | 2021-07-22 | 2023-03-22 | (주)이니바이오 | 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법 |
| US20250018016A1 (en) * | 2021-11-15 | 2025-01-16 | Medytox Inc. | Botulinum neurotoxin composition |
| TWI890364B (zh) * | 2023-03-16 | 2025-07-11 | 南韓商大熊股份有限公司 | 使用多模式層析法純化肉毒毒素的改進方法 |
| CN122514358A (zh) | 2023-09-19 | 2026-08-04 | 雷文斯治疗公司 | 需要快速起效美容效果和更平滑皮肤外观的患者中的使用肉毒毒素的治疗 |
| DE102025101336A1 (de) | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
| KR102945108B1 (ko) * | 2024-06-19 | 2026-04-02 | (주)제테마 | 클로스트리디움 보툴리눔 독소의 정제방법 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US796419A (en) | 1904-07-18 | 1905-08-08 | Carl Halbig | Doll-head. |
| SE303567B (cg-RX-API-DMAC10.html) * | 1959-02-17 | 1968-09-02 | Behringwerke Ag | |
| US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| WO1999037326A1 (en) * | 1998-01-26 | 1999-07-29 | University Of Massachusetts | Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| DE19925739A1 (de) † | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
| DK1301213T3 (en) * | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| GB2386246B (en) | 2001-11-01 | 2005-06-29 | Marconi Applied Techn Ltd | Electron beam tube apparatus |
| US7118901B2 (en) * | 2002-12-18 | 2006-10-10 | Roche Diagnostics Operations, Inc. | Recombinant bovine pancreatic desoxyribonuclease I with high specific activity |
| KR100498964B1 (ko) | 2003-03-05 | 2005-07-01 | 삼성전자주식회사 | 이동단말에서의 전자파 흡수율 제어 방법 및 장치 |
| AU2003271835A1 (en) * | 2003-06-06 | 2005-01-04 | Avecia Limited | Process for the separation of proteins |
| US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
| JP2007535911A (ja) * | 2003-12-30 | 2007-12-13 | バハラ バイオテック インターナショナル リミテッド | 組換えタンパク質の製造及び精製方法 |
| KR20050074806A (ko) * | 2004-01-14 | 2005-07-19 | 팜텍(주) | 결정형 보툴리늄 독소의 제조방법 |
| HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application and transdermal delivery of botulinum toxins |
| BRPI0508440A (pt) * | 2004-03-03 | 2007-07-24 | Revance Therapeutics Inc | composições e métodos para diagnóstico tópico e transporte terapêutico |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| HRP20090382T1 (hr) * | 2005-06-17 | 2009-09-30 | Merz Pharma Gmbh & Co.Kgaa | Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| EP2085093B1 (en) * | 2006-10-27 | 2015-02-25 | The Chemo-Sero-Therapeutic Research Institute | Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen |
| CN100588706C (zh) * | 2007-04-06 | 2010-02-10 | 常州千红生化制药股份有限公司 | 纯化弹性蛋白酶的方法 |
| AU2008256418A1 (en) * | 2007-06-01 | 2008-12-04 | Merz Pharma Gmbh & Co. Kgaa | Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form |
| JP5344558B2 (ja) * | 2008-10-31 | 2013-11-20 | 国立大学法人 東京医科歯科大学 | カチオン性ナノゲルを用いる粘膜ワクチン |
| LT2379104T (lt) * | 2008-12-31 | 2018-04-10 | Revance Therapeutics, Inc. | Injekcinės botulino toksino vaisto formos |
| US8440204B2 (en) * | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
| CN102869373B (zh) * | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
| US20120196349A1 (en) * | 2009-10-21 | 2012-08-02 | Revance Therapeutics, Inc. | Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin |
| US8440104B2 (en) * | 2009-10-21 | 2013-05-14 | General Electric Company | Kimzeyite garnet phosphors |
| US20150204884A1 (en) * | 2012-06-01 | 2015-07-23 | Momenta Pharmaceuticals, Inc. | Methods of evaluating and making biologics |
| WO2014066916A2 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| CN109069608A (zh) * | 2015-10-29 | 2018-12-21 | 雷文斯治疗公司 | 具有长的治疗或美容效应持续时间的可注射肉毒杆菌毒素制剂以及其使用方法 |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| AU2018270092C1 (en) * | 2017-05-18 | 2026-01-08 | Revance Therapeutics, Inc. | Methods of treatment for cervical dystonia |
-
2010
- 2010-10-20 US US13/394,506 patent/US20120196349A1/en not_active Abandoned
- 2010-10-20 CA CA2773396A patent/CA2773396C/en active Active
- 2010-10-20 ES ES10825598T patent/ES2688065T5/es active Active
- 2010-10-20 BR BR112012009227A patent/BR112012009227A2/pt not_active IP Right Cessation
- 2010-10-20 EP EP10825598.5A patent/EP2490986B2/en active Active
- 2010-10-20 HU HUE10825598A patent/HUE041599T2/hu unknown
- 2010-10-20 LT LTEP10825598.5T patent/LT2490986T/lt unknown
- 2010-10-20 PT PT10825598T patent/PT2490986T/pt unknown
- 2010-10-20 HR HRP20181869TT patent/HRP20181869T1/hr unknown
- 2010-10-20 PL PL10825598T patent/PL2490986T3/pl unknown
- 2010-10-20 CN CN201510173705.8A patent/CN104961812B/zh active Active
- 2010-10-20 US US12/908,647 patent/US20110092682A1/en not_active Abandoned
- 2010-10-20 RS RS20181330A patent/RS58006B1/sr unknown
- 2010-10-20 SI SI201031746T patent/SI2490986T1/sl unknown
- 2010-10-20 AU AU2010310749A patent/AU2010310749B2/en active Active
- 2010-10-20 DK DK10825598.5T patent/DK2490986T4/da active
- 2010-10-20 MX MX2012004703A patent/MX2012004703A/es active IP Right Grant
- 2010-10-20 MX MX2015011592A patent/MX365496B/es unknown
- 2010-10-20 KR KR1020127012224A patent/KR101819129B1/ko active Active
- 2010-10-20 SM SM20180487T patent/SMT201800487T1/it unknown
- 2010-10-20 PH PH1/2012/500549A patent/PH12012500549A1/en unknown
- 2010-10-20 WO PCT/US2010/053389 patent/WO2011050072A1/en not_active Ceased
- 2010-10-20 CN CN201080045567.0A patent/CN102666396B/zh active Active
- 2010-10-20 JP JP2012535338A patent/JP5951490B2/ja active Active
-
2012
- 2012-03-07 IL IL218532A patent/IL218532A/en active IP Right Grant
- 2012-04-20 MX MX2019006519A patent/MX2019006519A/es unknown
- 2012-04-30 CO CO12070154A patent/CO6551670A2/es not_active Application Discontinuation
-
2015
- 2015-07-10 US US14/796,235 patent/US9469849B2/en active Active
-
2016
- 2016-10-17 US US15/295,134 patent/US20170029795A1/en not_active Abandoned
- 2016-10-25 IL IL248486A patent/IL248486A0/en unknown
-
2018
- 2018-09-25 CY CY181100988T patent/CY1120908T1/el unknown
-
2019
- 2019-12-02 US US16/700,728 patent/US11466262B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11466262B2 (en) | Methods and systems for purifying non-complexed botulinum neurotoxin | |
| CN102482332B (zh) | 用于获得肉毒杆菌神经毒素的方法和系统 | |
| JP5518024B2 (ja) | 動物由来産物不含方法およびボツリヌス毒素を精製するための方法 | |
| RU2230325C2 (ru) | Способ приготовления очищенного препарата ботулинического токсина типа а | |
| HK1215951B (en) | Methods and systems for purifying non-complexed botulinum neurotoxin | |
| HK1175453B (en) | Methods and systems for purifying non-complexed botulinum neurotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |